176 results about "Hyperplasia" patented technology

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

1. Name of the product in this design: Wound Tension Relief Device (M Series 2). 2. Purpose of this design: To reduce the tension on both sides of the wound and prevent the wound from widening or hyperplasia due to excessive skin tension. 3. The key design feature of this product is its shape. 4. The picture or photo that best illustrates the key design points: Design 1 3D diagram 1. 5. The left and right views of Design 1-3 of this design have been shown in the perspective view, so the left and right views of Design 1-3 are omitted. 6. Design 1 is designated as the basic design.

A delivery device for positioning an implantable expander to a target location in a prostatic urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The invention provides a rhizoma bletillae composition as well as a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine preparations. The core effective component of rhizoma bletillae is rhizoma bletillae polysaccharide, the rhizoma bletillae polysaccharide has the effects of film forming, hemostasis, targeted wound repair promotion and infection prevention, tea polyphenol and rhizoma bletillae are compounded for use, the tea polyphenol and rhizoma bletillae synergistically resist inflammation, the expression quantity of proinflammatory factors IL-1beta, TNF-alpha and IL-6 is reduced by inhibiting NF-kappa B and MAPK signal channels, the inflammatory cascade reaction is remarkably blocked, and the anti-inflammatory effect is achieved. Red, swollen and pain caused by inflammation are effectively relieved, and wound healing is accelerated. In addition, the rhizoma bletillae and the tea polyphenol can also generate a synergistic antibacterial effect, and compared with a single rhizoma bletillae component, the probability of wound infection is further reduced; the compounding use of the rhizoma bletillae and the tea polyphenol also inhibits the excessive deposition of collagen, reduces the scar area, reduces the scar hyperplasia degree, and makes up the blank of only promoting healing and not preventing scars for burns and scalds in the prior art.

The invention provides a traditional Chinese medicine composition for preventing or treating prostatitis and a preparation method and application thereof, and belongs to the technical field of health care medicines. The traditional Chinese medicine composition is prepared from the following components: semen plantaginis, herba taraxaci, radix sophorae flavescentis, cortex phellodendri, radix salviae miltiorrhizae, radix et rhizoma rhei, radix rehmanniae praeparata, fructus ligustri lucidi, semen cuscutae, herba cistanche, fructus lycii extract, longan extract, membrane of hen egg, fructus ziziphi jujubae extract, honey and rice fermentation filtrate. The traditional Chinese medicine composition is in a liquid dosage form prepared by a process including fermentation treatment. The traditional Chinese medicine composition prepared by the invention can relieve prostate tissue edema of a prostatitis model rat in a dose-dependent manner and reduce a prostate wet weight index, so that the traditional Chinese medicine composition has a certain improvement effect on prostate tissue hyperplasia and inflammatory swelling caused by chronic abacterial prostatitis.

Computer-implemented methods for providing interactive electronic treatment assistance for benign prostatic hyperplasia and advanced prostate cancer are disclosed. The methods can include automatically sending, by a disease and disorder treatment device, an electronic pathway sign-up link to a smart mobile device. The method can include sending a plurality of inquiries about the BPH condition and / or the advanced prostate cancer condition, to the smart mobile device. The method can include receiving a plurality of patient responses from the smart mobile device. The method can include processing and storing the plurality of patient responses. The method can include providing, by the disease and disorder treatment device, patient education about various treatment therapies for advanced prostate cancer. The method can include automatically monitoring a patient having the advanced prostate cancer condition during the various treatment therapies. The method can include intervening with the various treatment therapies using the smart mobile device.

The invention discloses a traditional Chinese medicine composition for treating uroschesis caused by benign prostatic hyperplasia and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared by mixing leeches, radix semiaquilegiae, cortex phellodendri, rhizoma anemarrhenae, Chinese lobelia, polygonum cuspidatum, herba patriniae, dianthus superbus, cowherb seeds, lumbricus, pericarpium citri reticulatae viride and lindera aggregata and then decocting with water. According to the traditional Chinese medicine composition, treatment is carried out synergistically from the three aspects of rapid relieving of emergency symptoms, targeted treatment of pathologic roots and synchronous recovery of whole body metabolic balance, and the four-in-one comprehensive curative effect of diuretic, anti-male, anti-inflammatory and tissue repair is achieved; the traditional Chinese medicine composition is simple in preparation method, low in cost and wide in safety window, is applied to treatment of uroschesis caused by benign prostatic hyperplasia, and provides a family-friendly traditional Chinese medicine solution capable of replacing or being combined with existing chemical medicines for patients.

The invention relates to the technical field of biology, in particular to application of a prostate intermediate state cell and an inhibitor of the prostate intermediate state cell, and discloses application of the prostate intermediate state cell and an organ or tissue comprising the prostate intermediate state cell as a target in screening of drugs for treating prostatitis or prostatic hyperplasia. The prostate intermediate state cell inhibitor is applied to preparation of a medicine for treating prostatitis or benign prostatic hyperplasia; the inhibitor of the prostate intermediate state cells comprises one or more of a GRN signal channel inhibitor and a Sema4 signal channel agonist. The application provides a new therapeutic target for treatment of prostatitis or benign prostatic hyperplasia and drug screening, and provides a potential strategy for clinical treatment of prostatitis and benign prostatic hyperplasia.

The utility model relates to the technical field of medical instruments, in particular to a PEEK artificial bone material installation auxiliary instrument which comprises a face auxiliary limiting elastic cover used for conducting auxiliary limiting on PEEK artificial bone materials after face shaping and a nasal groove abutting device used for preventing nasal groove hyperplasia after nasal base filling. The face auxiliary limiting elastic cover comprises a cover body, a head circumference adjusting fastening belt and a top fixing belt, the cover body is matched with the human face structure, wearing ear through holes are reserved in the two sides of the cover body, a forehead through groove, an eyebrow bone eye through groove, a nose through groove and a lip through groove are sequentially formed in the cover body from top to bottom in a penetrating mode, and the forehead through groove is matched with the human forehead structure. The inner walls of the two sides of the forehead through groove are connected with forebone side face abutting plates with the postoperative forehead joint protruding. Through a plurality of fixing points and an adjusting mechanism, the stability and adaptability are improved, it can be ensured that the PEEK artificial bone material can be kept at an ideal position after an operation, the stability of an operation site is facilitated, the displacement risk is reduced, and the operation success rate is increased.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a composition in the preparation of a drug for treating diabetic wounds. The composition comprises the following components: *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone, with a mass ratio of 1:0.1-0.25:0.02-0.05. In this composition, *Artemisia capillaris* exosomes can penetrate the thickened inflammatory exudate layer and glycosylated extracellular matrix of diabetic wounds, reshaping the wound's immune repair microenvironment, promoting fibroblast activation and proliferation, regulating collagen synthesis and deposition, and reducing scar hyperplasia. 3-hydroxymorinogenone can increase vascular endothelial growth factor, promote angiogenesis, and thus promote the repair and healing of diabetic wounds. The synergistic effect of *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone in this composition significantly shortens the healing cycle of difficult-to-heal diabetic wounds and improves the quality of wound healing.

This invention discloses the application of two dipeptides in the preparation of a diagnostic kit for differentiating prostate cancer from benign prostatic hyperplasia (BPH). The invention reveals that the combination of the dipeptides H-Asp-Phe-OH (DF) and H-Leu-Ala-OH (LA) with prostate-specific antigen (PSA) has high diagnostic value in differentiating prostate cancer from BPH, with a high accuracy rate. The combined diagnostic effect of these three peptides is significantly better than that of PSA alone in differentiating between prostate cancer and BPH, showing promise for development into a diagnostic kit for differentiating prostate cancer from BPH.

Devices and systems are disclosed for managing and / or treating body tissues obstructing a hollow body lumen, including the prostatic lobe tissues obstructing the urethra, for example conditions including benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS). An implant is maintained in a constrained configuration within a distal portion of an elongated sheath so that is may be deployed by driving the implant with a pusher coaxially disposed within the sheath. An implant engaging element helps maintain control of the implant during deployment.

This invention discloses a traditional Chinese medicine composition for treating degenerative bone diseases, its preparation method, and its application. It is made from the following raw materials in parts by weight: 30-50 parts Rehmannia glutinosa (processed), 15-30 parts deer antler glue, 20-80 parts Cistanche deserticola, 15-50 parts Morinda officinalis, 15-50 parts tortoise shell glue, 30-80 parts Lycium barbarum, 10-50 parts Curculigo orchioides, 15-50 parts Eucommia ulmoides, 20-80 parts Cuscuta chinensis, and 30-50 parts Dioscorea opposita. 0 parts, Drynaria fortunei 15-50 parts, Achyranthes bidentata 10-50 parts, Taxillus chinensis 20-50 parts, Broussonetia papyrifera 15-30 parts, Clematis chinensis 15-50 parts, Acanthopanax senticosus 15-50 parts; Through the formulation strategy of "regulating the liver and kidneys, nourishing essence and blood, and combining tonification and purging", combined with a specific extraction process, it systematically regulates the balance of bone metabolism, achieves dual prevention and treatment of osteoporosis and bone hyperplasia, and treats both the symptoms and the root cause, and has high safety for long-term use.

This invention relates to the field of postoperative wound management technology, specifically to a method for intervening in abnormal scar hyperplasia after a cesarean section. The method includes the following steps: based on linear scar detection sites on the abdominal wall, the rebound temporal distribution characteristics are obtained; based on the changes in the rebound sequence, a segmented scar location structure is formed; the segmental nursing interval sequence is determined by combining the rebound arrangement relationship of each segment; nursing execution data is then generated according to the segmental location; and nursing rhythm changes are generated based on the differences in retesting. This invention calculates the recovery ratio based on displacement record changes and determines the rebound sequence to obtain temporal characteristics. By analyzing the internal temporal density, the order of segmental nursing is adjusted; the currently initiated segment is selected to optimize the application execution data; the records are rearranged to establish the nursing rhythm; and the unified treatment is transformed into a dynamic zonal intervention based on tissue elasticity. This eliminates the drawbacks of blind operation and ensures precise inhibition of tension concentration areas, comprehensively enhancing the targeted control of abnormal hyperplasia and improving the overall repair quality.

The invention discloses an anti-hepatic fibrosis traditional Chinese medicine compound preparation and application thereof.The anti-hepatic fibrosis traditional Chinese medicine compound preparation is prepared from herba artemisiae scopariae, parched fructus gardeniae, roasted rhizoma atractylodis macrocephalae, turtle shells, radix bupleuri, rhizoma corydalis, herba desmodii styracifolii and herba scutellariae barbatae, all the medicines are compatible and have a synergistic effect, and the effects of clearing heat and promoting diuresis, promoting blood circulation to remove blood stasis, softening hardness to dissipate stagnation and tonifying spleen and qi are achieved together; the liver fibrosis is intervened from a plurality of target spots. Heat clearing and diuresis promoting can eliminate damp-heat evil damaging the liver; blood circulation of the liver can be improved by promoting blood circulation to remove blood stasis, and blood stasis is eliminated; the liver fibrosis hyperplasia can be resisted by softening hardness to dissipate stagnation, and the liver tissue hardening trend can be reversed; spleen invigorating and qi replenishing can enhance healthy qi of the body and improve the self-repairing ability of the liver. The multi-target and all-around treatment mode not only conforms to the holism concept of traditional Chinese medicine, but also conforms to the understanding of modern medicine on multi-factor and multi-link pathogenesis of hepatic fibrosis.

A catheter for deploying an implantable expander in a urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

This invention relates to the field of image feature recognition technology, specifically to a method and system for locating key surgical points in orthopedic surgery based on anatomical structure feature recognition. The method includes the following steps: constructing a prior skeletal topology map representing biomechanical connectivity based on human anatomical standards; utilizing a graph attention mechanism to perform semantic mapping and feature aggregation between the multi-scale anatomical feature map and the prior skeletal topology map to generate node-enhanced feature vectors; and performing spatial coordinate regression calculations based on these node-enhanced feature vectors to output the coordinates of the surgical key points. In this invention, by introducing prior anatomical topological knowledge as a global constraint for feature extraction, the information transmission mechanism of the graph structure effectively captures the geometric dependencies between key skeletal points. This solves the problem of local feature ambiguity caused by traditional methods in complex pathological scenarios such as fracture displacement, bone hyperplasia, or tissue occlusion, achieving high-precision and robust surgical key point localization.

Some embodiments of the invention advantageously leverage the expansion of the prostatic urethra using adjustable lumen tension rings (ALTRs) of desired sizes to control and improve flow throughout the range of the urethra. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the prostatic wall and is at least partially within the lumen and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the bladder or other locations within the urethra and / or elsewhere in the urethra. The expansion of the lumen can be pre-configured based on pre-operative metrology of the prostatic urethra to a customized and adjustable fit across the various zones within the urethra and based on the patient specific and evolving needs.

The application discloses application of CFHR5 protein in preparation of a kit for diagnosing and distinguishing prostate cancer and benign prostatic hyperplasia. It is found by the application that the CFHR5 protein has high diagnostic value for distinguishing prostate cancer and benign prostatic hyperplasia, the accuracy of diagnosis and distinction is high, and the CFHR5 protein has the prospect of being developed into a kit for diagnosing and distinguishing prostate cancer and benign prostatic hyperplasia.

The invention provides a bisphenol A induced rat benign prostatic hyperplasia model and a construction method, and relates to the technical field of animal models. The method comprises the following steps: S1, selecting rats which are 8-9 months old and 9-10 weeks old, and adaptively feeding the rats in a suitable environment for 7 days or more; s2, jointly applying high-fat feed and bisphenol A to the adaptively fed rats to induce benign prostatic hyperplasia; the induction time is 60-80 days, and performing biological index evaluation after the induction is completed. The exposure level of low-dose BPA adopted by the invention is closer to the actual environment exposure level of people, and a main exposure way is simulated through oral gavage. The model constructed by the method can better simulate the real process of chronic and low-dose exposure pathopoiesis of the environmental endocrine disrupter in etiology, and provides an experimental tool with more practical significance for related risk evaluation.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

1. The name of the design product: hot steam treatment equipment. 2. The use of the design product: used with the prostate hot steam treatment instrument to relieve symptoms and obstruction related to benign prostatic hyperplasia (BPH). 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention discloses a traditional Chinese medicine composition for inhibiting and fading scar hyperplasia and a preparation method of the traditional Chinese medicine composition, and belongs to the field of traditional Chinese medicine compositions for fading scars. 5 to 15 parts of a gel matrix; 10 to 25 parts of an oil phase component; 3-8 parts of an emulsifier and a thickener; and the balance of water. Wherein the active traditional Chinese medicine component consists of 1-5 parts of calculus bovis factitius, 1-3 parts of artificial musk, 3-10 parts of cowherb seed, 3-10 parts of golden cypress, 2-8 parts of frankincense and 2-8 parts of myrrh. The traditional Chinese medicine composition for inhibiting and fading scar hyperplasia and the preparation method of the traditional Chinese medicine composition have the beneficial effects that the traditional Chinese medicine composition for inhibiting and fading scar hyperplasia and the preparation method of the traditional Chinese medicine composition are provided, all the medicines are combined to jointly achieve the effects of promoting blood circulation to remove blood stasis, dredging collaterals, removing stasis, resisting inflammation and promoting tissue regeneration and directly refer to the pathogenesis core of scar hyperplasia, and an oil-in-water (O / W) latex dosage form is adopted, so that the traditional Chinese medicine composition has the refreshing effect of gel and the moistening effect of cream, and is easy to coat and good in air permeability.

The invention discloses an application of cGAS as a target in prevention / treatment of Leigh syndrome. The method comprises the following steps: constructing NDufs4; a cGAS DKO gene knockout mouse model is researched, and the result shows that by knocking out cGAS, the glial hyperplasia phenomenon weakening of the mouse with the Like's syndrome can be improved, and neuroinflammation is inhibited. The invention provides a new potential drug target and a treatment strategy for treating the Like's syndrome, and lays a foundation for researching and developing a new drug for treating the Like's syndrome.

A stent is disclosed that is configured to maintain patency of the prostatic urethra despite an enlarged prostate. The stent can include a handle that, in an undeflected position, is disposed outside of the flow path of the stent. When the handle is pulled, the handle can deflect to generally aligned with a central axis of the stent. A capture device is disclosed that includes a tapered tip to navigate a working channel of a delivery device and a hook that can capture the stent handle and be moved into a tube to retain the stent handle to facilitate maneuvering of the stent in and out of the working channel of the delivery device. A loading adapter with a tapered port is disclosed that can be disposed on the delivery device to distribute compressive forces applied by the port on the stent during loading into the working channel.

The invention discloses a rapid scar-free healing device for limb and face sutured wounds. The rapid scar-free healing device comprises a supporting plate, a threaded bushing, a sliding column, an adjusting rod, a pressure bolt, a pan head pull rod, a push plate, a pressing plate, a breathable plate, a limiting pin, a tension spring, a hanging rod and a fastening belt. Through the retraction force of the tension spring, the push plate extrudes tissues on the two sides of a sutured wound to bulge towards the middle, and tissue tension is changed into tissue tightening force; the pressing plate and the breathable plate are pushed to move downwards through the pressure bolt, the protruding portion of the wound is wedged and flattened, tissues on the two sides of the wound are tightly attached in an airtight level, the butt joint and anastomosis speed of the tissues is increased, microorganisms can be effectively prevented from invading the wound, and infection is prevented. By flattening and suturing the convex part of the wound, the forced tissue hyperplasia can only be carried out subcutaneously, the body surface is always kept in a flat, smooth and non-hyperplasia state, and the sutured wound can be quickly healed without scars; the vertical pressure of the pressing plate and the transverse pushing force of the pushing plate can be steplessly adjusted through the pressure bolt and the adjusting rod so as to adapt to the tolerance of a patient.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

This invention discloses a biomarker, reagent kit, and system for diagnosing bladder injury secondary to benign prostatic hyperplasia (BPH), relating to the field of biomedical detection technology. The biomarker for diagnosing bladder injury secondary to BPH is characterized in that it includes urinary DAB2 protein. This invention achieves (1) clinical applicability: accurate quantitative assessment of the degree of injury. The most significant clinical value of urinary DAB2 protein lies in its ability to transform traditional subjective bladder injury assessment into an objective quantitative indicator. (2) convenient detection: non-invasive and rapid assessment using urine samples. As a urine detection biomarker, urinary DAB2 protein completely changes the traditional bladder injury assessment's reliance on invasive or expensive examinations such as cystoscopy and CT. (3) clinical decision support: the grading diagnostic value of urinary DAB2 protein is directly translated into clinical decision support capabilities, helping to avoid the clinical dilemma of "overtreatment" or "undertreatment."